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Computational delineation and 
quantitative heterogeneity analysis 
of lung tumor on 18F-FDG PET for 
radiation dose-escalation
Xiuying Wang1, Hui Cui1, Guanzhong Gong2, Zheng Fu3, Jianlong Zhou4, Jiabing Gu2, Yong Yin2 
& Dagan Feng1,5
Quantitative measurement and analysis of tumor metabolic activities could provide a more optimal 
solution to personalized accurate dose painting. We collected PET images of 58 lung cancer patients, 
in which the tumor exhibits heterogeneous FDG uptake. We design an automated delineation and 
quantitative heterogeneity measurement of the lung tumor for dose-escalation. For tumor delineation, 
our algorithm firstly separates the tumor from its adjacent high-uptake tissues using 3D projection 
masks; then the tumor boundary is delineated with our stopping criterion of joint gradient and intensity 
affinities. For dose-escalation, tumor sub-volumes with low, moderate and high metabolic activities 
are extracted and measured. Based on our quantitative heterogeneity measurement, a sub-volume 
oriented dose-escalation plan is implemented in intensity modulated radiation therapy (IMRT) planning 
system. With respect to manual tumor delineations by two radiation oncologists, the paired t-test 
demonstrated our model outperformed the other computational methods in comparison (p < 0.05) and 
reduced the variability between inter-observers. Compared to standard uniform dose prescription, the 
dosimetry results demonstrated that the dose-escalation plan statistically boosted the dose delivered 
to high metabolic tumor sub-volumes (p < 0.05). Meanwhile, the doses received by organs-at-risk (OAR) 
including the heart, ipsilateral lung and contralateral lung were not statistically different (p > 0.05).
Lung cancer is a major cause of cancer death worldwide1. The two major types of lung cancer are non-small 
cell lung cancer (NSCLC) and small cell lung cancer (SCLC). For SCLC patients, chemotherapy is an essential 
treatment procedure and radiation therapy (RT) may be a treatment option depending on the stage of cancer2. 
Treatment for patients with NSCLC may include various combinations of surgery, RT, chemotherapy and immu-
notherapy2–4, Most early-stage NSCLC patients are treated with surgery or stereotactic body radiotherapy (SBRT) 
that often has similar outcomes to surgery4. Chemotherapy in combination with radiation treatments are typically 
recommended for patients with stage III lung cancer2. In stage IV NSCLC, the choice of treatment depends on 
many factors and patients may also benefit from target radiation to residual lesions2. Thus, RT plays an essential 
role in lung cancer treatment. Nevertheless, there could be local tumor recurrence with RT. The mechanisms are 
unclear but they may relate to tumor heterogeneity, i.e differences in levels of hypoxia, cell density, tumor genetics, 
proliferation and vascularization2,3,5–8. Therefore, identification and analysis of tumor heterogeneity would be 
beneficial to tailoring treatment with RT in patients with lung cancer9,10.
Positron emission tomography (PET) is a functional imaging modality and plays an essential role in the diag-
nosis and staging of lung cancer. The primary clinical outcomes obtained from PET guided RT include target 
volume definition, nodal disease determination, RT planning modification, treatment response prediction and 
prognosis judgment10–12. For Fludeoxyglucose ([18F]FDG)-PET, the volumes of local relapse are correlated with 
high uptake regions which are treatment resistant areas13. In RT, to deal with the local recurrence, one solution is 
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to deliver increased dose to high [18F]FDG uptake regions while maintaining the dose to other parts of the heter-
ogeneous tumor by dose painting. Intensive research has investigated the relations between tumor sub-volumes 
with different metabolic activities and the survival outcome12,14–16. It has been proved that the localization and 
analysis of sub-volumes in metabolic tumor volume (MTV) are necessary for dose painting and precision person-
alized RT treatment planning9 using [18F]FDG- and [18F]flortanidazole (HX4)- PET/Computed Tomography(CT) 
imaging12–16.
The usual approach to define the boundaries of MTV and sub-volumes is by manual delineation. Manual 
delineation, however, is time consuming, labour intensive, operator-dependent17 and subject to inter- and 
intra-observer variations18,19. Most of the existing computational segmentation methods17,20 including our previ-
ous work21,22 focused on the overall tumor segmentation for accurate cancer diagnosis purposes. As the deline-
ation of complete tumor volume together with the measurement and extraction of metabolic sub-volumes from 
[18F]FDG-PET images are the basis of effective personalized treatment planning, and in order to better interpret 
the different levels of requests from diagnosis and treatment aspects, we propose an automated computational 
technique that delineates the target tumor and in the meanwhile, identifies and measures metabolic sub-volumes. 
A dose-escalation plan using the computational delineation and measurement results is performed by intensity 
modulated radiation therapy (IMRT) system. The technique is proposed with hope to provide second opinion for 
personalized precision RT treatment planning with radiation dose-escalation based on [18F]FDG-PET.
Materials and Methods
Patient studies. 58 [18F]FDG-PET/CT scans were retrospectively acquired in lung cancer patients. All 
patients were scanned on a Discovery LS PET-CT system (GE Healthcare, Milwaukee, WI, USA) after the injec-
tion of [18F]FDG. The patient studies enrollment criteria include: patients who received 60Gy (standard dose) and 
concurrent chemotherapy but had local recurrence; tumor exhibited inhomogeneous intensity distributions or 
indistinct boundaries. Among the patient studies, there are 30 cases with tumor infiltrating chest wall, 21 cases 
with tumor adjacent to mediastinum and 7 isolated cases. The PET images were reconstructed using a matrix 
of 144 × 144 pixels with a size of 4 mm × 4 mm × 4 mm; the CT images were reconstructed using a matrix of 
512 × 512 pixels with a size of 1.17 mm × 1.17 mm × 5 mm. The PET images were up-sampled to the size of CT 
to obtain a spatial correspondence between the volumes in a common space. Manual tumor delineations were 
drawn on the registered PET with CT images as reference by two radiation oncologists (referred to as Obs-1 and 
Obs-2) for automated segmentation accuracy evaluation.
All the data used in this study were approved by Medical Ethics Approval Committee at Shandong Cancer 
Hospital. All the patients consented to participate in this study and have signed a written informed consent doc-
ument. The methods were performed in accordance with relevant guidelines and regulations.
Automated target tumor segmentation. The proposed tumor segmentation framework is given in 
Fig. 1. The first step is to separate the target tumor from surrounding structures by extracting a 3D masking sur-
face (3D-MS). Secondly, a tumor customized boundary delineation method is proposed where the 3D-MS will 
shrink in a hill-climbing manner towards the tumor center until a joint stopping criterion is satisfied.
Figure 1. Outline of the proposed method. The max intensity projection (MIP) images of (a) input thorax 
volume are firstly extracted. (c) The separation masks are obtained by partitioning (b) the MIP images. (d) 
3D-MS of the reconstructed ROI (green object in (c)) is shown on coronal, sagittal and axial views. (e) The 
overall tumor segmentation by a hill-climbing shrinking method starting from 3D-MS. (f) 3D visualization of 
the segmented tumor volume; red, yellow and blue colour maps indicate high, moderate and less active sub-
volumes.
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Stage 1. The first stage is to initially extract a 3D-MS for tumor separation. As high FDG uptake tissues such 
as tumor appear as salient regions standing out from the background, given an input thorax volume and user 
defined seed for target tumor localization, max intensity projection (MIP) images are firstly generated along x, y 
and z coordinate directions. For the cases (as shown in Fig. 1(b)) where the tumor is attached to neighboring high 
uptake regions such as the heart, a saddle point where two salient regions attached is firstly located on each MIP 
image. Then the corresponding tangent line is generated to separate neighboring attached salient regions. The iso-
contour (Fig. 1(d)) passing through the saddle point is used to obtain a region of interest (ROI) mask. Finally, the 
seeds and ROI masks obtained from each of the MIP images are projected back to 3D space to generate 3D-MS.
Stage 2. Given the detected 3D-MS, the second stage is to shrink the surface towards the true tumor boundary. 
The aim of tumor segmentation can be considered as to assign each of the voxels inside 3D-MS a foreground/
tumor label lF or background label lB. To obtain the shrinking stopping criterion, we define the joint GM and 
intensity affinity of two adjacent voxels vi, vj as
φ β= − −v v exp g v g v( , ) ( ( ( ) ( ))) (1)i j j i
where the intensity-based affinity term 0β >  when f fi j>  where fi  denotes the average SUV value f within a 












 is a rotationally symmetric Gaussian low pass-filter where σ is the standard deviation, 
di denotes the distance from the origin in axis. The filter is applied to GM image to reduce the effect of noise while 
preserving the salient boundaries. In our experiments, β is set as 60 (−60) when 0β >  (β < 0) and σ is set as 1.5. 
It is noted that the absolute value of β in Equation (1) has no effect on the segmentation results because what 
matters is the condition of β being positive or negative. With φ defined as Equation (1), the segmentation is 
implemented in an iterative searching process by Algorithm 1.
Segmentation accuracy evaluation. To evaluate the segmentation accuracy of the proposed method, we calcu-
late the spatial overlap and shape dissimilarity between the automated segmented tumor volume (TVauto) and 
manually segmented tumor volume (TVmanual) by Dice similarity coefficient(DSC) and Hausdorff distance (HD) 
respectively. DSC and HD are defined as:
DSC TV TV TV TV
TV TV





| | + | |
=
∈ ∈ ∈ ∈
HD TV TV max d i j d i j( , ) { sup inf ( , ), sup inf ( , )}
(3)
auto manual
i S j S j S i Sauto manual manual auto
where S denotes the surface of a volume, sup represents the least subset element and inf  denotes the greatest sub-
set element; d is the Euclidean distance between points i and j. The DSC value is 1 for a perfect segmentation and 
a low HD value indicates high segmentation accuracy.
The performance of our method was compared with (1) a threshold of 40 % SUVmax, referred to as RG40; 
(2) a threshold of 50 % SUVmax, referred to as RG50; (3) iterative fuzzy c-means (FCM) clustering23, (4) a 
tumor-customized downhill model for PET segmentation (TCD)24, (5) a distance regularized level set evolution 
Algorithm 1. Pseudocode of the hill-climbing shrinking algorithm.
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(LSE)25, (6) an active contour for lung tumor segmentation (LAC)26; (7) random walk (RW)27 and (8) a local adap-
tive RW for PET segmentation (LARW)28. All the methods are implemented with MATLAB R2017a on a PC with 
3.50 GHZ Intel (R) Core (TM) i7-4770K CPU and 16.GB memory, running a 64-bit Windows operating system. 
RG40, RG50, FCM and TCD were implemented within a fixed bounding box of 60 × 60 × 20 voxels centred at the 
initial seed. The user seed was provided by a person with knowledge to identify a tumor.
Quantitative heterogeneity computing for dose-escalation. Heterogeneous sub-volume extraction 
and measurement. Metabolic sub-volumes are further segmented within our segmented tumor volume (TVPM) 
for heterogeneity measurement and dose-escalation purposes. We partition tumor sub-volumes with low, moder-
ate and high metabolic activities (referred to as TVlow, TVmod and TVhigh) using respective SUV ranges29 of (0,25%]
SUVmax, (25%,50%]SUVmax and (50%,100%]SUVmax. According to the calculation grid voxel size of the mainly 
used Treatment Planning System (TPS)30, a sub-volume whose size is smaller than 5 × 5 × 1 voxels is merged to 
the range of its nearest sub-volume and not counted as one isolated sub-volume.
Dose-escalation based on FDG-PET driven dose painting. The segmented tumor and metabolic sub-volumes 
are tested on Eclipse (Varian Medical Systems, version13.5) treatment planning system for dose-escalation in 
FDG-PET driven dose painting. Two six-field inverse-planned IMRT treatment plans are designed. One plan 
(plan A) is with uniform dose prescription of the entire tumor volume, the other comparative plan (plan B) is with 
sub-volume oriented dose-escalation based on our extracted metabolic sub-volumes. These two plans are set as:
•	 Plan A: a 10-mm margin is added to GTVmanual to create the planning target volume (PTVplanA). PTVplanA is 
prescribed a dose DPTVplanA where < <Gy D Gy60 66PTVplanA ;
•	 Plan B: PTVplanB is obtained as PTVplanB = PTVhigh + PTV mod + PTVlow where PTVhigh (PTVmod, PTVlow) is 
generated by applying a 10-mm margin to TVhigh (TVmod, PTVlow). The prescribed dose settings are: 
Gy D Gy Gy D Gy D Gy60 70 , 70 80 , 80PTV PTV PTVlow mod high< < < < > .
Method
Obs-1 Obs-2
DSC HD(mm) DSC HD(mm)
mean (SD) p-value mean (SD) p-value mean (SD) p-value mean (SD) p-value
RG40 0.68 (0.18) 2.2E-07 25.12 (16.56) 3.1E-05 0.71 (0.26) 4.2E-07 26.51 (18.06) 6.0E-06
RG50 0.58 (0.21) 5.3E-05 22.35 (14.13) 1.8E-06 0.62 (0.20) 6.5E-05 22.11 (14.01) 4.3E-05
FCM 0.69 (0.17) 4.7E-05 34.93 (18.76) 4.8E-06 0.73 (0.19) 5.5E-06 34.05 (21.00) 2.6E-07
TCD 0.63 (0.20) 6.1E-04 19.69 (15.20) 8.4E-05 0.67 (0.25) 5.2E-06 19.12 (15.18) 9.7E-04
LSE 0.80 (0.21) 1.1E-06 17.85 (8.34) 9.5E-05 0.81 (0.27) 3.7E-06 15.28 (9.06) 6.8E-05
RW 0.76 (0.52) 1.9E-05 18.61 (13.06) 1.1E-04 0.78 (0.23) 8.5E-04 17.51 (10.02) 2.5E-04
LARW 0.80 (0.17) 9.6E-04 13.19 (5.73) 8.1E-03 0.81 (0.25) 8.6E-04 12.87 (9.63) 9.9E-03
PM 0.84 (0.04) — 8.61 (3.12) — 0.85 (0.09) — 10.47 (6.54) —
Table 1. Segmentation evaluation results by DSC and HD (mm).
Figure 2. Two segmentation results shown in cropped PET (inverted for display) and CT images. The window 
width (W) and level (L) of the two sets of CT images are W: 350, L:35.
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Treatment plan evaluation. To compare the two treatment plas A and B, we calculate the dose distribution and 
dose-volume histogram (DVH) of PTV and organ-at-risk (OAR). OAR is manually delineated by experts on the 
planning PET/CT which includes the heart, ipsilateral lung, contralateral lung and spine cord.
Two heterogeneity indexes (HI), HIRTOG = Imax/RI and HID2,D9831 = (D2% − D98%)/Dp × 100, are calculated to 
evaluate the two plans, where Imax = maximum isodose in the target, RI = reference isodose, D2% and D98% rep-
resent the near-maximal and near-minimal dose respectively. If HIRTOG ≤ 2, the treatment plan is considered to 
comply with the protocol. A lower HID2,D98 value indicates a less heterogeneous target dose.
Results
Automated tumor segmentation performance. The inter-observer variation between obs-1 and obs-2 
was 0.824 ± 0.079 with respect to DSC and 8.99 ± 6.67 mm with respect to HD. As shown by Table 1, the pro-
posed method (PM) achieved the best tumor segmentation results with DSCs of 0.850 ± 0.044 and 0.847 ± 0.052, 
HDs of 7.47 ± 3.14(mm) and 7.38 ± 2.71(mm), followed by LSE and LARW. The improvement was statistically 
significant (p < 0.05). The computation time of the whole procedure by PM depends on the size of the lesion and 
was about 0.82 seconds for one slice. The time taken in initial tumor separation was about 0.68 second per case. 
The average computation time in tumor segmentation was 0.63 for one slice.
Two cases are shown in Fig. 2 where the tumor in Fig. 2(a) is with irregular margins and lies adjacent to the 
myocardium with similar FDG uptake. The local tumor extent is difficult to discern on PET. RG40, RG50, FCM 
and LARW failed in the tumor separation while LSE resulted in smaller tumor delineation and RW failed to 
delineate the whole tumor. PM was able to accurately separate the complete tumor from the surrounding struc-
tures with the DSC of 0.858 (Obs-1) and 0.831 (Obs-2), HD of 9.179 mm (Obs-1) and 9.356 mm (Obs-2) respec-
tively. For the case in Fig. 2(b), the tumor has heterogeneous FDG uptake reflecting regions of necrosis. RG40, 
RG50, FCM excluded the tumor regions with low SUVs and failed to delineate the whole tumor. PM obtained 
Figure 3. The extraction and measurement of metabolic sub-volumes and spatial SUV distributions of the case 
in Fig. 2(b). PTVhigh, PTVmod and PTVlow are shown by red, yellow and blue colors respectively.
Figure 4. Dose-Volume histogram (DVH) for the Planning target volume (PTV) and the organ at risk volume 
(OAR) in treatment plans A and B of the case in Fig. 3. Compared with plan A, the isodose contour of 20Gy (as 
pointed by the white arrow in coronal view) is much closer to the target volume and the radiation field width 
becomes shorter (as compared by red and yellow arrows) in plan B.
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the best tumor delineation with DSC of 0.943 (Obs-1) and 0.935 (Obs-2), as well as HD of 8.940 mm (Obs-1) and 
6.939 mm (Obs-2) respectively. TCD and LARW resulted in smaller tumor segmentation.
Heterogeneity measurement and dose-escalation analysis. The case in Fig. 2(b) with high hetero-
geneity is visually and quantitatively measured and analyzed as shown by Fig. 3. In this squamous cell carcinoma 
case, red, yellow and blue color maps are used to indicate the location and spatial relations of TVhigh, TVmod, 
TVlow in the ranges of (50%, 100%], (25%, 50%] and %(0, 25%] SUVmax. The TVlow s located near the tumor 
boundary were small, however, the intensities were greater than 23.86 % SUVmax which could be considered as an 
acceptable value for tumor definition in clinical practice32. In contrast, the SUV values of the other three larger 
TVlow s located closer to the tumor centre were as low as 8.24 % SUVmax. It can be learnt from the spatial SUV 
distributions that there were significant variations between the distributions of high, moderate and less active 
sub-volumes within this tumor.
For the case analyzed in Fig. 3, its DVH and isodose distributions of treatment plans A and B are given in 
Fig. 4. The tumor was located in the left upper lung and had denser and higher dose distributions in plan B than 
comparative plan A. As pointed by the white arrows in Fig. 4(a), the isodose contour of 20 Gy in plan B is much 
closer to the target volume than plan A, which indicated a lower dose received by contralateral lung. A decrement 
of radiation field width can also be observed in axial view. As shown by DVH in Fig. 4(b), plan B decreased the 
volume fractions of OAR when the isodose value was between 10 Gy and 60 Gy.
The dosimetry results of seven patients (characteristics listed in Table 2) with respect to PTV and OAR are 
given in Tables 3 and 4. All these cases complied with the protocol (HIRTOG ≤ 2). The PTV homogeneity was 
higher in plan A. As shown by Table 3, plan B resulted in a significant boost to the maximal (D2) and average 
(Dmean) doses received by PTV (p-values < 0.05). The doses received by OAR in plan B (shown by Table 4) were 
not statistically significantly different from that in plan A (p-values > 0.05).
Discussion
It has been proved that distinguishing tumor tissues with metabolic heterogeneity would be helpful for tumor cus-
tomized radiation dose painting and treatment13,33. With the development of IMRT, the dose escalation approach 
called simultaneous integrated boost (SIB) is able to deliver tailored doses to specific tumor sub-volumes with 
different metabolic levels29. Thus the accurate target tumor delineation and metabolic sub-volume extraction are 
important and essential in dose painting by contours or numbers in order to achieve high-quality RT results34.
We proposed an efficient and objective computational technique to outline the complete target tumor volume 
with heterogeneity, localize and measure tumor sub-volumes of different uptake ranges. The proposed method 
reduced the variability between inter-observers. Our major findings were: (1) The automatically extracted mask-
ing surface from MIP images was able to separate the tumor from its surrounding high FDG uptake regions 
and also provided an improved initialization for tumor delineation. Using the MIP images, the shape and size 
ID Location Age TNM Stage Pathology
PTV PTVlow PTVmod PTVhigh
ml ml % ml % ml %
1 L-U 68 T4N2M0 3b Squamous cell carcinoma 598.47 255.70 42.73 230.20 38.46 112.57 18.81
2 L-U 68 T4N1M0 3a Small cell carcinoma 618.05 243.16 39.34 201.39 32.59 173.50 28.07
3 L-L 60 T2N1M0 2a Adenocarcinoma 361.53 126.03 34.86 147.22 40.72 88.28 24.42
4 R-L 40 T2N2M1 4 Small cell carcinoma 968.54 563.77 58.21 442.76 45.71 37.99 3.92
5 M 59 T4N3M1 4 Adenocarcinoma 457.75 148.72 32.49 177.70 38.82 131.33 28.69
6 L-M 73 T4N3M0 3b Squamous cell carcinoma 394.16 228.06 57.86 112.64 28.58 53.46 13.56
7 R-U 63 T4N0M1 4 Non-small cell carcinoma 874.02 295.91 33.86 506.10 57.90 72.01 8.23
Table 2. Patient and tumor characteristics of seven male patients. L(R) - U(L) is used to indicate that the tumor 
is located in the left(right) upper(lower) lobe. M indicates that the tumor is located in the mediastinum, L-M 
represents the tumor locating in the left lung while being adjacent to the mediastinum.
ID
D2(Gy) D98(Gy) Dmean(Gy) HIRTOG HID D2, 98 V60(%)
A B A B A B A B A B A B
1 67.50 75.55 60.00 59.41 63.13 67.35 1.16 0.99 12.5 20.18 98.02 96.2
2 65.27 89.85 61.01 58.04 63.13 73.39 1.1 1.23 7.1 39.76 99.31 96.17
3 65.49 100.61 58.99 67.31 63.12 83.74 1.11 1.32 10.83 41.63 96.07 99.51
4 65.61 79.61 60.22 62.53 63.11 74.27 1.11 1.05 8.99 21.35 98.35 99.25
5 66.79 84.12 56.39 38.79 62.99 69.08 1.13 1.11 17.33 56.68 93.13 85.96
6 66.66 85.98 58.73 60.47 62.99 75.02 1.12 1.09 9.89 31.89 97.02 98.36
7 64.89 84.69 61.33 67.07 63.13 74.75 1.10 1.10 5.94 22.03 99.89 99.98
p-value — 0.0008 — 0.90 — 0.0015 — — — — — —
Table 3. Comparison between various metrics in plans A and B with respect to PTV. Dmean is mean dose; 
V60(%) = PTV volume receiving at least 60Gy; the p-value is calculated using two-tailed paired t-test.
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of the masking surface and the tumor were coherent. The first stage ensured that a contour is returned which 
topologically contains the ROI so as to avoid the exclusion of inhomogeneous areas within the tumor. The initial 
surface incorporated the whole tumor volume and avoided the variability in initialization. For those even more 
challenging cases when the tumor region has overlapping with surrounding high update regions on all the three 
projection views of MIP images, the first step with three directions might have difficulty in separation. In this 
case, we would suggest to increase the number of projection directions in our separation mechanism. (2) The pro-
posed hill-climbing stopping criterion achieved tumor-orientated boundary delineations which complied with 
manual definitions. This was because the shrinking of the initial masking surface towards the tumor avoided the 
over-segmentation caused by tumor heterogeneity. In addition, the joint affinity model of GM and intensity was 
able to obtain a balancing tumor-specified boundary identification. In our experiments over 58 cases, we found 
that the SUV values of our defined tumor boundaries were between 23.65 % and 37.76 % SUVmax, which also 
complied with the findings that a value ranging from 15 % to 50 % SUVmax could be used for tumor delineation32.
The quantitative extraction and measurement of tumor heterogeneity provided insightful information of 
tumor metabolism which assisted inhomogeneous dose calculation and treatment response monitoring and 
assessment. Our heterogeneity quantitative measurement results were tested on IMRT planning system to per-
form a dosimetry comparison between a dose-escalation plan and a standard uniform dose prescription plan. The 
evaluation results of seven patient studies demonstrated that the dose-escalation plan statistically significantly 
boosted the dose delivered to the tumor sub-volumes with high metabolic activities. In the meanwhile, the doses 
received by OAR including the heart, ipsilateral lung and contralateral lung were not statistically and significantly 
increased. The results revealed that by using the sub-volume oriented dose-escalation plan, the dose delivered to 
the target tumor can be boosted while preserving the dose delivered to OAR.
With the proposed method, the accurate segmentation of target tumor volume and measurement of heteroge-
neous sub-volumes would be beneficial to tumor metabolism analysis, heterogeneous dose calculation and esca-
lation in FDG-PET driven dose painting by contours or numbers so as to improve the local disease control rate 
(DCR). The proposed model may also contribute to image-centric prediction models such as survival prediction 
and treatment response prediction following treatment by chemotherapy, radiotherapy, and hypnotherapy. Given 
the PET images obtained at different scanning time intervals or treatment stages, the proposed technique would 
be able to quantitatively track the re-distribution of metabolic sub-volumes. For patients with NSCLC, molecu-
larly targeted therapy using epidermal growth factor receptor (EGFR) inhibitors is well developed. Thus, future 
studies may include FDG PET/CT data before and after targeted therapy and then analyze the dynamic changes 
of MTV in segmented areas as well as texture parameters. By such, it could continuously monitor and evaluate the 
therapy responses and thereby could make contributions to personalized treatment plans.
ID OAR
D2(Gy) D98(Gy) DMean(Gy) V5(%) V10(%) V20(%) V30(%)
A B A B A B A B A B A B A B
1
Heart
61.89 62.83 0.93 0.85 15.15 13.74 47.92 46.53 40.11 38.32 30.00 26.26 18.67 16.23
2 45.61 43.55 0.51 0.52 6.66 6.38 27.07 23.58 19.18 16.36 11.23 9.91 5.38 6.89
3 55.75 58.36 6.84 6.72 18.95 21.93 98.89 98.85 77.97 93.35 37.90 50.70 13.90 17.68
4 63.71 70.81 2.26 2.20 20.85 23.12 84.41 82.60 66.12 66.11 36.23 47.52 22.32 26.63
5 62.86 72.79 0.70 0.73 18.69 19.01 57.96 57.65 49.35 48.54 39.12 37.05 27.82 27.39
6 56.06 60.02 0.13 0.16 5.46 5.91 16.69 17.61 13.32 13.68 9.88 10.46 6.34 6.48
7 29.74 32.79 0.38 0.51 4.14 4.67 17.51 19.06 11.81 13.23 4.74 5.53 1.95 2.53
p-value — 0.05 — 0.74 — 0.26 — 0.35 — 0.50 — 0.34 — 0.28
1
Ipsilateral lung
62.44 66.80 0.90 0.85 22.93 21.27 63.00 61.33 56.55 54.62 48.86 43.79 35.95 32.56
2 63.09 71.53 0.86 0.89 21.61 18.65 50.43 47.32 43.41 39.45 39.06 33.65 35.35 28.06
3 64.17 88.12 0.95 1.04 23.10 27.27 68.84 67.54 60.56 59.44 49.39 48.25 31.81 38.50
4 63.73 77.40 2.75 3.13 38.89 45.57 86.55 89.98 76.03 79.89 69.86 73.02 64.84 68.34
5 63.31 52.63 1.12 0.81 19.63 17.98 64.92 61.54 51.59 47.64 36.65 33.51 26.13 21.49
6 63.46 76.64 0.29 0.33 19.37 22.62 49.06 52.47 42.33 45.85 37.27 40.84 31.74 36.28
7 63.67 78.7 1.09 1.29 21.63 25.49 54.54 57.11 47.07 48.07 40.86 42.38 34.50 36.60
p-value — 0.06 — 0.54 — 0.28 — 0.99 — 0.77 — 0.54 — 0.92
1
Contralateral lung
33.11 27.75 0.53 0.50 10.54 8.81 60.18 56.85 46.00 40.48 10.94 5.29 2.64 1.53
2 21.38 26.76 0.36 0.40 4.67 5.23 34.14 31.34 13.02 17.66 2.54 4.84 0.31 0.95
3 19.29 19.85 0.72 0.78 5.20 5.84 49.44 52.10 10.50 15.14 1.52 1.94 0.00 0.01
4 22.70 23.92 0.93 0.97 5.05 4.82 24.11 22.22 18.06 15.46 4.01 4.93 0.21 0.64
5 48.90 52.63 0.73 0.81 10.86 11.43 42.81 44.55 32.02 31.91 23.12 23.37 11.42 13.52
6 6.58 4.66 0.06 0.06 0.74 0.69 2.66 1.88 0.78 0.69 0.36 0.30 0.10 0.02
7 42.27 49.27 0.65 0.76 8.43 9.66 35.41 38.77 27 29.11 17.84 20 5.08 6.50
p-value — 0.39 — 0.05 — 0.71 — 0.89 — 0.77 — 0.96 — 0.27
Table 4. Comparison between various metrics in plans A and B with respect to OAR.
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Limitations. The dose prescriptions in treatment plan B were designed to evaluate the proposed computa-
tional technique in dose-escalation to tumor sub-volumes with varying metabolic activities. Although the plan 
complies with protocol, it is not guaranteed that this is a most optimized plan. As this is a retrospective study, the 
treatment response using this plan in clinical practices has not been evaluated in this work.
Conclusion
We proposed an automated target tumor delineation and quantitative tumor heterogeneity analysis approach. 
The experimental results proved that our method achieved improved segmentation accuracy. The dose-escalation 
plan using our heterogeneity measurement boosted the tumor sub-volumes with varying metabolic activities 
while controlling the dose livered to the organs at risk. This technique would offer an efficient way to assist the 
precise radiation therapy procedures, particularly for the lung cancer patients who need personalized dose paint-
ing to achieve high-quality RT results and deal with the local recurrence. The treatment response using the pro-
posed method in clinical practices should be evaluated before its wide application.
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